|Day Low/High||0.66 / 0.70|
|52 Wk Low/High||0.60 / 2.15|
They're the most important executive at most small developmental or early commercialization concerns.
BioDelivery Sciences, Neos Therapeutics and Invitae Corp. are delivering big increases in sales.
I continue to see these names as bargains in the biotech and biopharma space.
Novartis' deal for AveXis has ignited a rally in other gene-therapy concerns.
A look at possible second-quarter M&A activity in the biotech sector.
Markets have improved somewhat in the past 90 minutes. The Dow and S&P 500 are now in the black with other major indices nearing even. Some quick observations about some stocks with less than two hours left to end the week. AbbVie clawing back a tad...
3pm blog update Heading into the homestretch of the trading week. All the major indices remain firmly in the green. Small biotech is having a very strong day, up about two percent this Friday. Some small cap movers today. Synergy Pharmaceuticals nic...
Winning FDA approval isn't always a win.
The experiences of three biotechs show how drug approvals don't always translate into stock gains.
Dynavax Technologies, Ocular Therapeutix and Neos Therapeutics have big drug approval dates ahead.
The two sectors hold more promise than most in the back half of 2017.
Three small-cap biotechs with attractive risk/reward profiles.